Professor David Newby graduated from the University of Southampton with a Bachelor of Science and Bachelor of Medicine degree in 1991. He has worked in Edinburgh for nearly 15 years and obtained Doctorate of Medicine and Doctorate of Philosophy degrees. Professor Newby is currently British Heart Foundation Professor of Cardiology at the University of Edinburgh, Translational Professor for the Translational Medicine Research Collaboration, Director of the Wellcome Trust Clinical Research Facility, Director of the Clinical Research Imaging Centre, Director of Research and Development for NHS Lothian and a Consultant Interventional Cardiologist at the Royal Infirmary of Edinburgh.
Professor Newby’s principal research interests are in endothelial and vascular biology, acute coronary syndromes and heart failure; focusing on clinical experimental and translational medicine. He currently holds a Programme Grant from the British Heart Foundation to explore the adverse cardiovascular effects of air pollution. Professor Newby is involved in several multicentre trials and has played a major role in the conduct of the SALTIRE (Scottish Aortic stenosis Lipid lowering Trial, Impact on REgression) and 3CPO (Health Technology Assessment trial of non-invasive ventilation for acute cardiogenic pulmonary oedema) trials. For his research, he was awarded the British Association of Pharmaceutical Physicians’ Prize, the Croom Lectureship (Royal College of Physicians, Edinburgh), the BUPA research award for the best emerging clinical researcher in the UK, and the John French Lectureship (British Atherosclerosis Society). He has written several successful educational books that have received major national awards (British Medical Association Book Awards, Highly Commended: Coronary Heart Disease: Your Questions Answered; Society of Authors, First Prize (Richard Asher Prize): Cardiology: An Illustrated Coloured Text).
Professor Newby currently sits on the Editorial Board of the Journal of the American College of Cardiology, Arteriosclerosis Thrombosis and Vascular Biology, Biochemical Pharmacology and Heart. He is a member of the Project Grant Committee of the British Heart Foundation, and the Biomedical and Therapeutics Research Committee of the Chief Scientist’s Office at the Scottish Executive. Professor Newby was the Vice Chair for the development of the Scottish Intercollegiate Guideline Network (SIGN) guidelines for the management of acute coronary syndromes. He currently sits on the UKCRN Experimental Medicine Advisory Group and Cardiovascular Speciality Subgroup.